NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness

About this update from Netramark Holdings Inc

Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged AM Public Relations (AM PR), a healthcare-focused public relations agency specializing in media relations, thought leadership, and strategic communications for healthcare and technology companies. The engagement is intended to support NetraMark's broader communications strategy as the Company continues to advance its proprietary NetraAI platform and expand industry relationships. This work with AM PR aims to communicate NetraMark's scientific, clinical, and commercial progress to key audiences, including investors, potential partners, industry stakeholders, and the broader healthcare community. "This engagement comes at an important time for NetraMark as we continue to build awareness of our platform, our partnerships, and the role NetraAI can play in helping pharmaceutical and biotechnology companies generate more meaningful insights from clinical trial data," said George Achilleos, Chief Executive Officer of NetraMark. "As the market increasingly recognizes the need for explainable AI in drug development, we believe it is important to communicate our progress clearly, consistently, and to the right audiences. AM Public Relations brings experience in shaping complex stories for broader visibility, and we look forward to working with them as we continue to advance NetraMark's strategic objectives." AM PR specializes in strategic communications for healthcare and technology companies to communicate complex science, technology, and innovation to investors, customers, partners, and the media. "NetraMark is tackling one of the biggest challenges in clinical development: helping researchers generate more meaningful insights from complex clinical trial data," said Ashley Moore, founder and CEO of AM PR. "As the company continues to grow, we'll help communicate the science behind the platform, the impact it's having for customers, and the broader role explainable AI can play in the future of drug development." For more information on NetraMark and NetraAI, visit www.netramark.com . About NetraAI NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting," which drowns out critical information that could have been used to improve a trial's chance of success.

View stock analysis, news, and events for Netramark Holdings Inc